Search

Displaying results 2031 - 2040 of 10000 in total
  1. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    This approval was based on favorable results obtained from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period. … [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022.

  3. Drug

    Nitazoxanide

    go.drugbank.com/drugs/DB00507
    ApprovedInvestigationalVet approved

    Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment … microaerophilic bacteria, in addition to viruses.

    Products: N/a, XINPA 2 % POLVO PARA RECONSTITUIR A SUSPENSIÓN ORAL
  4. Drug

    Cabergoline

    go.drugbank.com/drugs/DB00248
    ApprovedInvestigational

    Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. … Cabergoline possesses potent agonist activity on dopamine D2 receptors.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
  5. Drug

    Acetohydroxamic acid

    go.drugbank.com/drugs/DB00551
    ApprovedInvestigational

    Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.

    Synonyms: N-Hydroxyacetamide, N-Acetylhydroxylamine
  6. Drug

    Varicella zoster vaccine (recombinant)

    go.drugbank.com/drugs/DB13924
    ApprovedInvestigational

    The main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV). … Herpes zoster, also known as shingles, is caused by a reactivation of Varicella Zoster Virus (VZV), the virus that commonly causes Chickenpox in childhood.

    Synonyms: gE recombinant Varicella zoster virus (VZV) glycoprotein E, Recombinant Varicella zoster virus (VZV) glycoprotein E
  7. Drug

    Echothiophate

    go.drugbank.com/drugs/DB01057
    ApprovedInvestigational

    A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.

    Synonyms: 2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodide
  8. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to [iloperidone] in vivo. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]

  9. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    This binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. … It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue

  10. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    [A260122,A260127] Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family. … Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.